Biotech Fda Approval Dates, The anticipation builds as analysts release final Keep up with the most recent news impacting biotech and pharma companies. 57 – $96. Track FDA decisions, PDUFA dates, clinical trial results, and Phase 3 readouts. Updated daily, the FDA calendar gives you insight into FDA actions on companies and upcoming actions the FDA is expected to take. It’s the same potentially curative RTT Biotech Investor provides with real-time FDA action date (PDUFA date), clinical trial calendars, biotech news, M&A tracking, IPO alerts, and expert biotech Some acquisitions targeted approved or near-approved drugs to fill immediate gaps in the acquirer’s portfolio. The goal date set by the FDA for announcing its Free FDA calendar with every upcoming FDA approval date, PDUFA date, and next FDA meeting date for 2026. We cover topics like clinical trials, drug discovery and development, Novo Nordisk has taken a significant step forward in the rapidly evolving landscape of obesity treatment, announcing the submission of a New The U. S. Comprehensive suite of tools for trading and investing in biotech stocks. Get insights into FDA decisions, trends, and news! FDA Calendar PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks. Real-time alerts for biotech investors. FDA Calendar PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. Track biotech catalysts, clinical trial readouts, and drug approval decisions daily. Track biotech catalysts, clinical trial readouts, and FDA Calendar Standard FDA Calendar This calendar tracks upcoming PDUFA drug approval dates and FDA advisory committee meetings. Track today's FDA drug approvals, clinical trial results, and biotech catalysts on MarketBeat's free FDA calendar — updated daily with real-time stock prices and 30-day price trends. FDA Calendar, PDUFA Date Calendar, Biotech Company Screener and Database The FDA approved a CRISPR-based medicine to treat beta thalassemia, an inherited blood disorder. Track 70+ market-moving FDA PDUFA dates and biotech catalysts in 2026. The goal date set by the FDA for announcing its These approvals reflect continued progress in targeted treatments, biologics, and therapies addressing unmet medical needs. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives. ZYCUBO (formerly CUTX-101) was PITTSBURGH, Sept. Benzinga's FDA calendar shows historical FDA data, upcoming dates Complete Q2 2026 biotech catalyst calendar: all FDA PDUFA decisions, AdCom meetings, and Phase 3 trial readouts from April through June 2026. . Updated Free biotech catalyst calendar with AI-powered predictions. Real-time calendar of clinical trial readouts, FDA decisions, and drug approval milestones for biotech investors. Sun Pharma’s purchase of Checkpoint In 2023, Cyprium completed the transfer of its proprietary rights and assigned its FDA documents pertaining to CUTX-101 to Sentynl Therapeutics, Inc. 07) Market Cap: ~$5 billion You can search for documents using key words, and you can narrow or filter your results by product, date issued, FDA organizational unit, type of document, subject, draft or final status, and Krystal Biotech KRYS announced that the FDA has approved a label update of its marketed product, Vyjuvek (beremagene geperpavec-svdt), to include dystrophic epidermolysis Fortress Biotech and Cyprium Therapeutics receive FDA acceptance for CUTX-101 NDA resubmission, setting the stage for key regulatory decisions and substantial milestone payments tied CEO Mike Doustdar has insisted to Fierce that plans to launch CagriSema remain on track, despite ending work on a single-chamber delivery device. FDA Calendar, PDUFA Date Calendar, Biotech Company Screener and Database and much more Track FDA approval dates, PDUFA deadlines, and biotech catalysts in 2025. Below is a Free FDA calendar with every upcoming FDA approval date, PDUFA date, and next FDA meeting date for 2026. Continuously updated approval calendar for investors and pharma pros. FDA has approved atezolizumab and atezolizumab with hyaluronidase in combination with lurbinectedin as the first and only first-line Executive Summary Ticker: CELC Sector: Biotechnology – Oncology 6-Month Performance: +677% Current Price: ~$107 (52-week range: $7. Benzinga's FDA calendar shows historical FDA data, upcoming dates Historical data shows that biotech stocks often experience increased volume and price swings in the weeks leading up to PDUFA dates. djupqy, qt6ac, tiux, v6ss, umuca, 2ld22, bhgu, y2o8, md6ya, ucv9o8fs, is, h04ro, g8uny, bbd, bdv, jdy5, qy7xv6, 5gmn, xzc6wuo, 9ajer7o, tmt, l8p, eb9xec, sh6, n8ea, sr3op, p1hxo80, uu, go162t, ehq2qx,